KAVITA SURA: Open Payments
NPI 1811433345 · LILLINGTON, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$599 in 31 payments from 9 companies in 2025. Trend: 2023 $378 · 2024 $749 · 2025 $599
Food & beverage: $599
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 10 | $189 |
| ABBVIE INC. | 8 | $153 |
| AstraZeneca Pharmaceuticals LP | 3 | $53 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $44 |
| GlaxoSmithKline, LLC. | 2 | $44 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $42 |
| Amgen Inc. | 2 | $30 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| Lilly USA, LLC | 1 | $18 |
Products named: VRAYLAR, Ozempic, Wegovy, Kerendia, SHINGRIX, JARDIANCE, AIRSUPRA, OTEZLA.
Industry payments across NC — which companies pay providers there.
